A r t i c l e s
For nearly a decade, hundreds of millions of dollars per year have been spent on the discovery of putative protein biomarkers of human diseases, especially plasma biomarkers. Despite this substantial investment, the number of new US Food and Drug Administration-approved biomarkers in plasma approved annually has remained relatively static, at no more than two per year 1 . This low yield is especially disappointing in the light of the revolution in technologies for discovering biomarker candidates, which has enabled the identification of hundreds of biomarker candidates for each of the most extensively studied diseases.
Several factors have contributed to this low return on investment. First, although so-called ' omics technologies have revolutionized the discovery of candidate biomarkers, the majority of these candidates do not encode clinically actionable information even if they differ in abundance in disease and control samples. Second, biomarker discovery experiments are fraught with false discoveries resulting from biological variability and the large number of hypotheses being tested in small numbers of samples. Furthermore, because there are no validated approaches for prioritizing from among the droves of candidates those likely to be of clinical use, costly clinical validation studies must be performed on large numbers of candidates for a single novel biomarker of clinical utility to be identified. Third, because there are no quantitative assays for the majority of human proteins 2 , assays (typically enzyme-linked immunosorbent assays (ELISA)) must be developed de novo for clinical testing of candidate biomarkers, and de novo assay development is prohibitively expensive for testing large numbers of candidate biomarkers. As a result, few putative biomarkers undergo rigorous validation, and the literature is replete with lengthy lists of candidates without follow-up.
Hence, current practice in typical biomarker discovery projects consists of the following stages. First, ' omics technologies are applied to plasma, proximal fluids and/or solid tissues to identify hundreds of candidate biomarkers. Next, candidate biomarkers undergo 'verification' in which each putative biomarker is quantified in a limited number (tens to hundreds) of clinical samples to confirm differential expression of the candidate in plasma from cases versus controls. Finally, beyond verification studies, clinical validation requires a large-scale case-control or cohort study to carefully examine the impact of other covariates on the proposed marker test, to determine the positive predictive values and false referral probabilities in real practice, and to compare or combine the new test with existing clinical tests. Because the odds are extraordinarily low that any one candidate will encode clinically useful information, large numbers of candidates must be tested if there is to be any hope of identifying a clinically useful biomarker. Thus begins a desperate search of commercial sources for antibodies and immunoassays for quantifying the candidates. Unfortunately, no assays are available for the vast majority of human proteins, and 50-60% of commercially available antibodies are so poorly validated as to be useless [3] [4] [5] , resulting in a considerable waste of time and money. Novel ELISA assays are extremely expensive to generate and very difficult to multiplex. Ideally they also require a recombinant protein standard, and because many proteins cannot be purified to a single component in a soluble form, the failure rate can be quite high. Thus, if one is to test more than a few dozen A targeted proteomics-based pipeline for verification of biomarkers in plasma High-throughput technologies can now identify hundreds of candidate protein biomarkers for any disease with relative ease. However, because there are no assays for the majority of proteins and de novo immunoassay development is prohibitively expensive, few candidate biomarkers are tested in clinical studies. We tested whether the analytical performance of a biomarker identification pipeline based on targeted mass spectrometry would be sufficient for data-dependent prioritization of candidate biomarkers, de novo development of assays and multiplexed biomarker verification. We used a data-dependent triage process to prioritize a subset of putative plasma biomarkers from >1,000 candidates previously identified using a mouse model of breast cancer. Eighty-eight novel quantitative assays based on selected reaction monitoring mass spectrometry were developed, multiplexed and evaluated in 80 plasma samples. Thirty-six proteins were verified as being elevated in the plasma of tumor-bearing animals. The analytical performance of this pipeline suggests that it should support the use of an analogous approach with human samples.
A r t i c l e s candidate biomarkers (for which there are good commercially available assays) one must generate novel, analytically validated assays de novo. Because of the high costs associated with de novo assay generation, a small number of candidate biomarkers must be selected from the many hundreds of available candidates, and there is no validated method to guide the prioritization of candidates. As a result, despite tremendous effort, each biomarker project in the end faces little more than a stochastic chance of success.
Until technologies exist to enable high-content, quantitative proteomic profiling on large numbers of clinical samples, a successful biomarker development pipeline must enable triaging and measuring large numbers of candidates downstream of biomarker candidate discovery, thereby accommodating the presently inevitable high per-candidate failure rate. The recent emergence of targeted mass spectrometry (MS)-based proteomic technologies, such as accurate inclusion mass screening 6 (AIMS) and selected reaction monitoring [7] [8] [9] [10] [11] (SRM) , has raised the possibility [12] [13] [14] [15] of using these technologies for data-dependent triage and testing of hundreds of candidate biomarkers in a time-and cost-effective manner. Unlike untargeted (shotgun) modes of MS frequently used in biomarker candidate discovery studies, targeted MS methods are peptide sequence-based modes of MS that focus the full analytical capacity of the instrument on tens to hundreds of selected peptides in a complex mixture 16, 17 . By restricting detection and fragmentation to only those peptides derived from proteins of interest (that is, candidate biomarkers identified in biomarker discovery experiments), sensitivity and reproducibility are improved dramatically compared to discovery-mode MS methods.
Although targeted MS-based technologies have been proposed as the basis of a viable biomarker pipeline 12, 13, 15, [18] [19] [20] , no such pipeline has been demonstrated. Implementing such a notional pipeline is a substantial undertaking involving protocol development and benchmarking. The purpose of this study was to test the hypothesis that the analytical performance of a staged biomarker pipeline based on targeted MS would be sufficient for (i) data-dependent prioritization of hundreds of candidate biomarkers, (ii) de novo development of tens to hundreds of assays of sufficient precision, specificity and sensitivity for human studies and (iii) multiplex biomarker verification studies allowing testing of tens to hundreds of candidate biomarkers in hundreds of clinical samples while consuming a minimal volume of biospecimen material.
For decades, animal models have been critical for testing hypotheses before undertaking human studies. Using a mouse cancer model for this technology benchmarking study was advantageous because (i) samples could be easily generated and collected under strict standard operating protocols in a cost-effective manner, (ii) biological and environmental variations could be minimized and strictly controlled for, allowing us to focus on the pre-analytic and analytic variations associated with the technologies and (iii) precious human clinical samples were not consumed. Although biological variation among humans will undoubtedly be greater than that among mice, the preanalytic and analytic variations associated with the technologies are agnostic as to what species is used. Thus, although specific biomarkers identified in a mouse model may not be relevant to human disease, the mouse is a useful model system for benchmarking technologies intended for clinical applications.
RESULTS

Biomarker candidate identification
We selected a mouse model of breast cancer that has been extensively characterized using genomic and proteomic technologies [21] [22] [23] [24] . Therefore, considerable data were available for identifying putative circulating biomarkers at the outset of the study. Candidate biomarkers (1,908; Supplementary Worksheet 1) were identified by integrating 13 independent genomic and proteomic data sets 21, 22 , including candidates discovered in tumor tissue (and predicted to be secreted, leaked or shed) and/or in plasma (fig. S1.1 and table S1.2 in Supplementary Results Section 1). Quantitative assays (e.g., ELISAs) were not available for the majority of the candidates, severely limiting our ability to perform follow-up verification studies of candidates.
To triage and verify a large number of biomarker candidates, we configured a pipeline ( Fig. 1) using targeted proteomic technologies, strategically staged in a manner intended to enable us to test as many candidates as possible while containing costs. Specifically, the technology with the lower expense and higher capacity to triage large numbers of candidates (AIMS) was used first, whereas the lower capacity and more expensive quantification technology (SRM) was used last (on only the most highly credentialed candidates).
Biomarker candidate prioritization (AIMS and SQ-SRM)
It is imperative to choose from among the large number of initial candidates and identify those most likely to be of use as a blood-based A r t i c l e s marker before committing resources to quantitative assay configuration. Because many candidates originate from discovery experiments based in tissue (or proximal fluids), and the number of candidates from this category may be very high (table S1.2 in Supplementary Results Section 1), the approach used should have a large capacity for determining the presence of each candidate in plasma. We chose to use AIMS 6 for this purpose. For AIMS analysis, peptide mass-to-charge ratios (m/z) on a usergenerated software inclusion list are monitored in each scan using an Orbitrap MS system, and MS/MS spectra are acquired only when a peptide from the list is detected with both the correct accurate mass and charge state 6 . The fragmentation patterns from these acquired spectra are used to confirm the presence of the peptide. We used AIMS 6 to confirm that a given peptide (and thus the protein from which it is derived) was detectable in the plasma (and thus might form the basis of a blood-based test), providing a bridge from discovery to MS-based targeted assay development. Only candidates detected in the plasma by AIMS were advanced to assay development. The AIMS study is described in detail in Supplementary Results Section 2. Briefly, a pool of plasma with equal contributions from 20 tumor-bearing animals was collected, abundant plasma proteins were depleted, and plasma was proteolyzed with trypsin and subjected to strong cation exchange (SCX) chromatography to generate ten fractions. Each fraction was subjected to 21 AIMS runs and six liquid chromatography (LC)-MS/MS shotgun runs. For AIMS analysis, we targeted 16,961 proteotypic peptides (experimentally observable peptides that each uniquely identify a specific protein or protein isoform) from 1,144 candidate biomarkers. Of these, 764 candidates were not targeted owing to capacity limitations and the absence of empirical proteotypic peptides; 572 candidates (50%) were detected (Supplementary Worksheet 2) . The highest success rates for detection (table S2.2 in Supplementary Results Section 2) came from those candidates identified in both tissue and plasma (79%) and those discovered in plasma but not tissue (77%). An interesting feature of this analysis is the reasonably high (17%) success rate for candidates originally discovered exclusively in the tissue data sets.
AIMS analysis added little benefit (1-5% additional candidates) over the standard shotgun analysis for candidates that had previously been discovered in plasma (table S2.3 in Supplementary Results Section 2). The added value of the inclusion list was quite apparent for candidates previously identified exclusively in tumor tissue, where a large number (n = 48; 26% additional candidates) of candidates discovered in tissue were confirmed by AIMS only (that is, not detected by shotgun analysis). This was expected because candidates originally discovered only in tissue are likely present at a lower concentration in plasma compared with those candidates discovered directly in plasma; thus the use of the inclusion list (and associated added sensitivity) is beneficial.
Reagent costs (e.g., synthetic stable isotope-labeled standard (SIS) peptides) prevented us from developing quantitative SRM assays for all the candidates confirmed by the AIMS analysis, necessitating a further prioritization step. For this we used a semiquantitative application of SRM 25 that involves normalization of signals, as described below. In the targeted SRM mode of MS, a specific tryptic peptide is selected as a stoichiometric representative of the protein from which it is cleaved. For semiquantitative SRM (SQ-SRM) evaluation, SRM signals from housekeeping proteins (that is, plasma proteins with the same abundance in tumor-bearing and control animals) were used to normalize SRM signals from candidate proteins across LC-SRM-MS runs (Supplementary Worksheet 3) . The AIMS/shotgun data were used to empirically select 9,647 transitions (i.e., a pair of precursor and fragment ion m/z for a given peptide) representing 383 candidates that were measured in triplicate on depleted plasma pooled from 20 tumor-bearing mice and 20 control mice. Of these, 189 candidates were not targeted because the observed peptides did not meet our SRM peptide criteria (Supplementary Results Section 3) . SRM signals were curated by hand to ensure proper peak integration and retention time alignment of multiple transitions emanating from each peptide; only transitions showing consistency across runs with a signal-to-noise ratio ≥8 were included in the analysis. Candidates were binned based on confidence level (figure s3.2 in Supplementary Results Section 3). High confidence was assigned to the 164 candidates for which we detected at least three transitions from at least one proteotypic peptide. Medium confidence was assigned to the 38 candidates for which we detected two transitions from one proteotypic peptide. The remaining 171 candidates were detected by a single transition only and thus were considered to be unsubstantiated. The 164 high-confidence candidates were further prioritized by receiver operating characteristic (ROC) analysis (Supplementary Results Section 3), narrowing the list to those 118 candidates with ROC > 0.7. Thus the triage step was successful in narrowing the number of candidates to a reasonable and manageable list, and for determining the subset of candidates for which an antibody (that is, immuno-SRM assay) would be required for robust measurement.
Ninety-one proteins were selected for de novo quantitative assay generation (Supplementary Results Section 3) . Seven candidates were selected from the housekeeping proteins and 49 candidates were selected from the high-confidence candidates, whose transition signals are likely to be sufficient for quantification by SRM-MS. To evaluate the false-negative rate of the pipeline for prioritizing viable lower abundance candidates, we also selected an additional 35 candidates for which signals in the SQ-SRM analysis were too low for assessment. For these 35 candidates, we generated affinity-purified, polyclonal antibodies for immunoaffinity enrichment of proteotypic peptides upstream of SRM-MS. This technique, stable isotope standards and capture by antipeptide antibodies 26 (SISCAPA), achieves limits of quantification (LOQ) of proteins in the low ng protein/ml range 21,27-29 from 10 µl and low pg protein/ml range 29 from 1 ml plasma. Development and characterization of the SRM and immuno-SRM assays are described in the following sections.
Quantitative SRM (Q-SRM) assay development We configured 57 peptide analytes (representing 49 candidates and seven housekeeping proteins) into a multiplex SRM-MS assay, and SIS peptides were used as internal standards (Supplementary Results Section 4 and Supplementary Worksheet 4a-c). A list of peptides and SRM transitions is provided as a Skyline document; see Supplementary Data 1. The analytical performance of the multiplex assay was determined by generating response curves for candidate biomarkers in a trypsinized, depleted plasma matrix (Supplementary Appendix A). Performance characteristics of the assays for the candidate biomarkers are summarized in Table 1 . The median analytical coefficient of variation (CV) across all analytes was 5.7% at the LOQ. The median limit of detection (LOD) was 68 ng protein/ml plasma, and median LOQ was 157 ng protein/ml plasma.
Quantitative immuno-SRM assay development
We developed 31 affinity-purified polyclonal antibodies to proteotypic peptides from 30 of the 35 selected candidates described above, and these antibodies were used to construct a 31-plex immuno-SRM assay, using SIS peptides as internal standards (Supplementary Results
Section 5 and Supplementary Worksheet 5a-d). A list of peptides
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and SRM transitions is provided as a Skyline document; see Supplementary Data 2. The analytical performance of the 31-plex assay was determined by generating response curves in a trypsinized plasma matrix (Supplementary Appendix B) . Performance characteristics of the assays are summarized in Table 2 ; median CV across all analytes was 7.4% (triplicate SISCAPA captures), median LOD was 26 ng protein/ml plasma and median LOQ was 48 ng protein/ ml plasma. Note that LOD/LOQs are not directly comparable to those for the multiplex Q-SRM assay described above, as the Q-SRM assays tested a different set of analytes and were run on depleted plasma using a Qtrap 5500 instrument, whereas immuno-SRM assays were run on nondepleted plasma using a Qtrap 4000.
Verification studies
The analytically validated, 57-plex SRM and 31-plex immuno-SRM assays were used in a quantitative biomarker verification study Three to four transitions were measured for each target in the equivalent of 1.5 µl of depleted plasma, and three repeats (three LC-SRM-MS analyses) were performed at ten concentration points (and a blank sample). The best transition for each target was selected as the basis for the quantitative assay. A linear regression algorithm was used for fitting the ten serial dilution data points for each curve. The LOD of each target was obtained from the average of the blank measurements plus three times the s.d. The LOQ was obtained from the average of the blank measurements plus ten times the s.d. with additional criteria that the CV of measurements of the concentration points near the calculated LOQ were <25% 40, 41 . Protein LOD/LOQ estimates assume complete trypsin digestion.
Assays followed by an asterisk (*) were characterized by reverse curves, as described in Supplementary Results Section 4. ROC curves and corresponding AUC values were determined for each candidate, and P values were determined by permutation testing, as described in Supplementary Results Section 6. Candidates determined to be significantly elevated (that is, verified; AUC ≥ 0. 
A r t i c l e s (Supplementary Results Section 6).
No mice used for discovery, AIMS or SQ-SRM were used for the verification studies, which used a separate cohort of animals. All 88 assays were run in triplicate on 80 plasma samples derived from three cohorts of mice, as described below (Supplementary Worksheet 6a-g and Supplementary Appendix C). Median assay precision (during the verification studies) was 3.4% CV (analytical variation) for the 57-plex SRM and 12.5% CV (preanalytical and analytical variation combined) for the 31-plex SISCAPA assays. The first cohort included ten control and ten tumor-bearing mice, where tumors were clinically apparent (~1 cm, equivalent to the tumor burden in the mice used for discovery). For the 57-plex assay, Results shown are derived from the SRM-MS-based measurements in Supplementary Worksheet 6a (worksheet labeled "clinically apparent"). Gray and blue data points represent Q-SRM data, whereas orange and red data points represent immuno-SRM data. Cases and controls were matched with respect to age and gender, housed in the same cage, euthanized on the same day, and derived from different animals than those used in the discovery and prioritization experiments. (Although Aldoc and Chi3l1 meet significance based on P-values, their levels are near their assay LODs.) CA, clinically apparent tumors; CTRL, matched controls. Three to four transitions were measured for each target in the equivalent of 10 µl of digested plasma, and three repeats (three SISCAPA process replicates) were performed at ten concentration points (and a blank sample). The best transition for each target was selected as the basis for the quantitative assay. A linear regression algorithm was used for fitting the ten serial dilution data points for each curve. The LOD of each target was obtained from the average of the blank measurements plus three times the s.d. The LOQ was obtained from the average of the blank measurements plus ten times the s.d. with additional criteria that the CV of measurements of the concentration points near the calculated LOQ were <25% 40, 41 . Protein LOD/LOQ estimates assume complete trypsin digestion. Assays for candidates followed by asterisk (*) were characterized by reverse curves, as described in Supplementary Results Section 5. ROC curves and corresponding AUC values were determined for each candidate, and P-values were determined by permutation testing (Supplementary Results Section 6). Candidates determined to be significantly elevated (that is, verified; AUC ≥ 0.8 and P ≤ 0.01) in the plasma of animals with clinically apparent tumors are in boldface. Peptide sequences are abbreviated to the first four amino acids (full sequences are shown in Supplementary Worksheet 5a).
A r t i c l e s 46 of the targeted peptide analytes were present above their assay LOQs in at least 50% of the cancer-bearing animals (Supplementary Worksheet 6a). Thirty proteins (2310057J18Rik, Aldoc, Chi3l1, Comp, Ctsb, Ctsl, Dsg2, Ext2, Fetub, Fn1, Hsp90b1, Hspa5, Itih3, Kng2, Lcn2, Lcp1, Mug1, Nrp1, Orm2, Spp1, P4hb, Papln, Pdia3, Ppic, Ptk7, Ptprf, Spint1, Tnc, Itih1, Pzp) showed significant elevation in tumor-bearing animals (area under the curve (AUC) ≥ 0.8, P ≤ 0.01; Table 1 ). These success rates indicate that the SQ-SRM analysis of pooled plasma successfully identified candidates that (i) could be measured by SRM in depleted plasma without antibody enrichment, and (ii) had a high probability of being verified in quantitative studies examining individual (that is, not pooled) plasma samples. For the 31-plex immuno-SRM assay, 17 of the analytes were present above their assay LOQs in at least 50% of the cancer-bearing animals (Supplementary Worksheet 6a) . Of these, six proteins (B4galnt1, Ext1, Man2a1, Mfge8, Pcdh18, Prdx4) showed significant elevation in tumor-bearing animals (AUC ≥ 0.8, P ≤ 0.01). The results are summarized in Table 2 , and representative examples are shown in Figures 2-4 . Where available, commercial antibodies were used for western blot analysis or ELISA of plasma and confirmed the results of the SRM-based assays (Figs. 3, 4 and figure S6.4 in Supplementary  Results Section 6 ). These results demonstrate that generation of an anti-peptide antibody and configuration of an immuno-SRM assay enhanced the SRM signals from target analytes, allowing quantification in plasma.
A higher percentage of candidates assayed by Q-SRM (30/56 or 54%) were verified compared to the number verified using immuno-SRM (6/35 or 17%). This is expected because the immuno-SRM targets were unsubstantiated by SQ-SRM and likely represent lower abundance proteins. Consistent with this, 46/57 Q-SRM analytes were above their assay LOQs in at least 50% of the cancer-bearing animals, whereas only 17/31 were for the immuno-SRM analytes.
The second cohort included ten control and ten tumor-bearing mice, where the tumors were preclinical (that is, not palpable); hence, the tumor burden was considerably lower than that used in the biomarker discovery work. This second time point was examined to determine whether the SRM technology is sufficiently sensitive to quantify biomarkers that are only fractionally elevated as A r t i c l e s a consequence of an extremely low tumor burden. For the 57-plex SRM assay, 29 of the targeted analytes were present above their assay LOQs in at least 50% of the cancer-bearing animals (Supplementary Worksheet 6b). Of these, one protein (Spp1) was present at significantly (P ≤ 0.01) elevated levels in tumor-bearing animals. For the 31-plex SISCAPA assay, 20 of the analytes were present above their assay LOQs in at least 50% of the cancer-bearing animals. Of these, one protein (Mfge8) was present at significantly (P ≤ 0.01) elevated levels in tumor-bearing animals. Hence, as expected, detection of very low disease burden is far more challenging than detection of high disease burden.
To determine the specificity of the biomarkers elevated in cancer, we tested a third cohort of 10 control mice and 30 mice that had been injected with a compound to stimulate confounding conditions including inflammation, apoptosis, necrosis, wound healing and angiogenesis (Supplementary Results Section 6 ). Of the 36 proteins elevated in the plasma of animals with clinically apparent breast cancers, 17 were above their assay LOQ in at least 50% of the animals with the confounding condition. Only two proteins (Pdia3, Ppic) were elevated in a confounding condition (AUC ≥ 0.8, P ≤ 0.01), suggesting that the majority of biomarkers tested are not general indicators of inflammation or tissue remodeling.
The distribution of the discovery methods used to identify the verified candidates is shown in table S6.1 in Supplementary Results Section 6. The number of candidates tested in this study makes it difficult to draw conclusions regarding the general success rates of various discovery approaches. It is noteworthy that a high percentage of candidates that had been discovered exclusively in tissue-based analyses were substantiated by Q-SRM (4/4) and immuno-SRM (3/15).
DISCUSSION
The purposes of this study were to develop protocols and procedures for a large-scale biomarker pipeline based on targeted MS and to test the hypothesis that the pipeline would be sufficient to support largescale clinical biomarker studies in humans. Previous work has characterized the performance of the individual components in isolation, such as AIMS, SRM and immuno-SRM technologies. Nonetheless, they had not been assembled in a pipeline, and were generally carried out in small numbers of reference samples and small numbers of analytes, inadequate to demonstrate the feasibility of deploying them in clinical studies.
To be useful for human biomarker studies, a pipeline must enable (i) data-dependent prioritization of hundreds of candidate biomarkers, (ii) cost-effective de novo development of tens to hundreds of assays of sufficient precision, specificity and sensitivity for human studies and (iii) multiplex biomarker verification studies allowing testing of tens to hundreds of candidate biomarkers in hundreds of clinical samples while consuming a minimal volume of biospecimens.
Based on these criteria, the procedures and protocols we have described, along with our benchmarking activities, demonstrate that the analytical performance of the targeted proteomic pipeline should be sufficient to support large-scale verification studies in humans.
First, the AIMS and SQ-SRM stages of the pipeline enabled data-dependent prioritization of hundreds of candidate biomarkers. Because of the ability to schedule AIMS detection based on the known or predicted retention times of the target peptides, >1,000 parent ions can be monitored in a single LC-MS/MS run, enabling a large number of candidates to be screened for detection in plasma in a single run. This high capacity enables prefractionation of plasma, thus enabling detection of analytes in the low ng protein/ml plasma range (levels consistent with many known cancer biomarkers). Of the 1,908 candidates identified from genomic and proteomic data sets, proteotypic peptides could be identified for 1,551 candidates (81%). This already high coverage will expand further as ongoing projects designed to characterize proteotypic peptides for all human proteins mature (http://www.mrmatlas.org/). Of the 1,144 candidates targeted for detection in plasma by AIMS, ~50% were detected in plasma, despite the fact that many of the candidates had been discovered in tumor tissues, not plasma.
Although AIMS provided confirmation that a candidate biomarker could be detected in the plasma of tumor-bearing animals, it did not provide quantitative comparison of the levels of the candidates in cases versus controls. The gold standard for quantitative MS in the clinical laboratory is SRM-MS, which has been used for decades to quantify small molecules in human blood samples 30 . An isotopically labeled internal standard typically is used for rigorous quantification, but label-free approaches provide a potential cost-effective method for rapid semiquantitative screening of large numbers of candidates 25 . In this study we normalized the SRM signals of candidate biomarkers to those from a set of housekeeping proteins each of whose abundances did not, on average, differ between cases and controls (Supplementary Results Section 3) . Three hundred eightythree of the 572 candidates (67%) detected in plasma were associated with proteotypic peptides that met criteria for SRM-based quantification (Supplementary Results Section 3 ). Of these, 373 (97%) contained transitions that were reproducibly detectable with a signal-to-noise ratio ≥8, and were thus analyzed by SQ-SRM in pooled case versus control plasma to estimate whether the corresponding biomarker candidates were differentially abundant and thus might be useful biomarkers.
By far, the most challenging stage of the pipeline was verifying the specificity of the detected transitions in SQ-SRM. The difficulty resulted from the lack of internal standards, which provide reference signals for the verification of analyte specificity. Thus, in our experiment, the choice of candidates for quantitative SRM assay development was limited to the most abundant proteins or peptides for which multiple transitions were identified. For example, of the 373 analytes tested, only 164 (44%) were associated with at least three transitions with perfectly aligned retention times, indicating high confidence for specificity of the detection for the targeted analyte. Indeed 171 of the 373 analytes (46%) could not be substantiated with confidence, owing to difficulty in detecting transitions. The use of more affordable, albeit less pure, stable isotope standards from a process generally referred to as spot or membrane synthesis 31 remains to be tested but may offer a viable, cost-effective, alternative strategy to circumvent this issue. Furthermore, the specificity in SQ-SRM could also be improved by using recent advances in the data-dependent inclusion of transitions, such as intelligent SRM 32 . It is notable that the success rate in verifying the credentialed candidates was very good (36/91 candidates or 40%). Therefore, MS-based techniques can be used to triage candidate biomarkers.
The second activity that a biomarker pipeline must support for human studies is the cost effective de novo development of tens to hundreds of assays of sufficient precision, specificity and sensitivity for human studies. The cost of reagents for generating Q-SRM assays are those of the SIS peptides, for which heavy-light pairs can be obtained for <$1,000 per analyte. Reagent costs for generating a novel immuno-SRM assay with >90% success rate is <$5,000, and the average yield of an affinity-purified polyclonal antibody allows for testing of hundreds of plasma samples to assess the utility of a A r t i c l e s marker before investing in monoclonal antibody development 33 . Lead time for assay generation is ~24 weeks, including selection of proteotypic peptides, synthesis of immunogens, generation of antibodies, optimization of assay conditions and generation of response curves. In this study, 88 novel assays were developed and characterized in <1 year by one laboratory. In contrast, it would be extraordinary for a single academic laboratory to successfully configure 1-10 ELISA assays de novo in 1-2 years, especially at a comparable cost.
Regarding precision, as precision of the assay deteriorates, there is a nonlinear increase in the dispersion of the results, and thus the clinical signal may be drowned out by analytical noise. For example, biomarker measurements using an assay with poor precision will have a broader reference interval (due to analytical variation) and will thus be of less value for clinical classification of patients. As discussed elsewhere 20 , statistical verification of a novel biomarker showing comparable biological variation to prostate-specific antigen would require testing plasma samples from a minimum of 500 cases and 500 wellmatched controls using an assay technology associated with CV ≤ 20%. In this study, we observed CV < 15% for the majority of assays, demonstrating the feasibility of our approach for human biomarker verification studies.
Beyond verification studies, true clinical validation will require an even larger-scale case-control or cohort study to carefully examine the impact of other covariates on the proposed marker test, to determine the positive predictive values and false referral probabilities in real practice, and to compare or combine the new test with existing clinical tests. In the field of clinical chemistry, quality specifications for assay precision are routinely based on biological variation 34 . It is widely accepted among clinical chemists 34 that the desirable level of imprecision in measurements should be <50% of the average withinsubject variation (in which case the amount of variability added to true test-result variability is ~10%). Where desirable performance standards are not attainable with current methodology, the minimum level of imprecision in measurements should be <75% of the average within-subject variation (in which case the amount of variability added to true test-result variability is ~25%). Across 163 protein analytes for which human biological variation has been determined (http://www.westgard.com/biodatabase1.htm), the median withinsubject biologic variation is 10%; hence, the median desirable specification for assay precision is 5%. Achieving this very high bar for clinical implementation of the immuno-SRM assays in hospital laboratories will likely require optimization of the individual assays on an analyte-by-analyte basis.
Regarding specificity, SRM-based assays have a distinct advantage over conventional immunoassays, which are prone to interferences 35 . With SRM, assay specificity is ensured by monitoring multiple transitions from each analyte and by inclusion of an internal isotopically labeled standard. Furthermore, where interferences are present, they are readily detected and can be avoided by selection of alternative transitions.
Regarding sensitivity, many known human cancer protein biomarkers are in the ng-to-pg of protein/ml plasma concentration range; early disease detection, such as in cancer, may require much higher sensitivities. In this study, assay LOQs in the low ng protein/ml plasma range were typically achieved when starting with only 10 µl of plasma (small volumes were used in this study due to the limited plasma yield from individual mice). However, immuno-SRM assays can achieve low pg protein/ml plasma LOQs when capturing from higher plasma volumes 29 . Immuno-SRM assays are readily amenable to the testing of hundreds of biospecimens in human studies, as sample handling is minimal and largely automated and performed in a 96-well format 29, 33 . In contrast, for Q-SRM studies (without an anti-peptide antibody), sensitivity remains the primary obstacle to use of SRM assays, without enrichment of the target analyte. Coupling SRM with abundant protein depletion and sample fractionation significantly improves LOQs [36] [37] [38] , but multiplex assay configuration may be difficult for hundreds of candidates, and the intensive sample processing required has a great impact on sample throughput. Hence, for large-scale biomarker verification studies on hundreds of plasma samples, it is beneficial to generate an antibody for immuno-SRM measurements, obviating the need for depletion or fractionation.
The third activity that a biomarker pipeline must support for human studies is multiplex biomarker verification studies that permit testing of tens to hundreds of candidate biomarkers in hundreds of clinical samples 20 , while consuming a minimal volume of biospecimens per analyte. The SRM technology is highly amenable to multiplex measurements, as demonstrated in this study and others 39 . Current instrumentation and software allow for scheduling of the transitions being monitored (based on peptide retention times on the high-performance liquid chromatography (HPLC) column), theoretically enabling hundreds of peptide analytes to be quantified in a single LC-MS run. The high multiplex level of these technologies also allows a very large number of measurements to be made in a relatively short period of time, accelerating progress from the discovery step to verification. For example, in this study 80 plasma samples were run in triplicate for 88 analytes, totaling 21,120 assays run in one laboratory in <6 months, demonstrating the feasibility for human biomarker studies. The ability to test ten to hundreds of biomarker candidates in multiplex also makes the use of larger plasma volumes a viable option for early human biomarker studies, allowing for increased assay sensitivity (as discussed above).
In this study, we demonstrate that a staged, targeted proteomic pipeline enables triage and follow-up quantitative testing of a far larger number of candidates than would have been possible using conventional technologies, marking a substantial improvement over the current state of biomarker evaluation. Although the true impact of this or any biomarker development pipeline will not become apparent until it is successfully used to discover novel biomarkers in humans, this study uses an animal model to benchmark the performance of the proposed pipeline and thereby demonstrates the feasibility of, and thus sets the stage for, applying the pipeline to human biomarker studies. Because biological and disease subtype heterogeneity (pre-analytical variables) likely differ between mouse models and humans, biomarkers identified using mice will not necessarily be of clinical utility in humans. Nonetheless, because the analytical performance of the technologies (e.g., sensitivity, precision, specificity and multiplex characteristics) as well as pre-analytical sample processing are not species-specific, we can confidently extrapolate the analytic performance observed using a mouse model to analogous studies with humans, even if the specific biomarkers are of limited clinical potential.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
Accession codes. All data used by or generated during this study have been deposited in the public domain. Hash codes from the ProteomeCommons.org Tranche network for the plasma AIMS data, shotgun data and integrated SRM data are given in Table 3 . Additionally, Skyline documents for implementing the 57-plex SRM (Supplementary Data 1) and the 31-plex immuno-SRM (Supplementary Data 2) assays are available. 
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ONLINE METHODS
See Supplementary Methods for a description of reagents, mouse models, peptide quality control, depletion and digestion of pooled samples, SCX, the AIMS experiment, ELISAs, western blot assays and statistical analysis.
Semi-quantitative selected reaction monitoring (SQ-SRM).
The same LC configuration and eluting gradient for the AIMS experiments was used to schedule the SQ-SRM targets using the empirical retention time obtained from the AIMS experiments (Supplementary Results Section 2) . A hybrid triple quadrupole/linear ion trap mass spectrometer (4000 QTRAP, ABSciex) with a nano electrospray interface was used for the SRM analyses. The instrument was controlled by Analyst 1.5 software (ABSciex) and operated in the positive ion mode. Typical instrument settings included a spray voltage of 2.3 kV, a nebulization gas setting (GS1) of 15, an ion source temperature of 150 °C, and Q1 and Q3 set to unit/unit resolution (0.7 Da). The scheduled SRM option was used for all data acquisition with about 1,100 transitions per run, a target scan time of 3 s and a 15 min SRM detection window. Transition lists included 191 transitions from the 56 housekeeping peptides in addition to the candidate peptide transitions. All SQ-SRM runs were performed in triplicate. SRM data were processed using MultiQuant 1.1 (ABSciex) with the MQL algorithm for peak integration. A 7-point smooth with a peak-splitting factor of 2 and the default MultiQuant values for noise percentage and baseline subtraction window were used. Transitions for the peptide of interest were required to have similar retention times (±7.5 min) in normal and cancer samples and multiple transitions to the same peptide were required to have the same retention time within an LC-MS run. All data were manually inspected to ensure correct peak detection and accurate integration. A signal-to-noise threshold of 8 was used to distinguish robust signals from the background. Further details are provided in Supplementary Results Section 3.
Response curves. Two types of response curves were generated by QSRM and SISCAPA-SRM (Supplementary Results Section 4 and 5), one for which the light peptide concentration was varied (forward curve) and one for which the heavy isotopically labeled peptide concentration was varied (reverse curve). The latter was used to assess the lower limits of detection and quantification in cases where endogenous light peptide caused the forward response curve to level off before the signal intensity had reached noise levels (Tables 1 and 2) .
The response curves for biomarker candidates in the QSRM samples consisted of 11 points, with 1:4 serial dilutions. The starting concentration varied for each analyte, based on the expected concentration of the endogenous peptide (Supplementary Worksheet 4b) . The internal standard concentrations also varied based on the endogenous peptide concentration. Depleted and digested mouse plasma (Sigma-Aldrich) was prepared as a diluent for each response curve point. A list of peptides and the associated transitions and instrument parameters for the biomarker candidates is presented as Supplementary Worksheet 4a. The optimized transitions for each biomarker candidate were configured into a single multiplex assay by scheduling the transitions by retention time. Scheduled SRMs were set up using a 420 s SRM detection window and a 1.5 s cycle time. Three technical repeats (separate LC-SRM-MS injections) were performed at ten concentration points (and a blank sample). The best transition (determined by highest signal-to-noise and lowest background levels) for each target was selected as the basis for the quantitative assay, and the remaining transitions were used as 'qualifiers' to ensure a high specificity (see Supplementary Worksheet 4c for a list of transitions used in quantification).
The response curves for the SISCAPA samples consisted of 11 points (Supplementary Worksheet 5b) starting with 500 fmol/µl in a capture and subsequent 1:4 serial dilutions, and the internal standard concentration was 10 fmol/µl. Three capture replicates were performed for each concentration point, and 10 µL of digested mouse plasma (Sigma-Aldrich) was used for each capture. A list of peptides and the associated transitions and instrument parameters for each analyte in the 31-plex SISCAPA method is presented in Supplementary Worksheet 5c. The captures and further sample processing steps were performed as for the preclinical and confounding samples below, using 1 µg of anti-peptide antibody for each analyte. The best transition (determined by highest signal-to-noise ratio and lowest background levels) for each target was selected as the basis for the quantitative assay; remaining transitions were used as 'qualifiers' to ensure a high specificity (see Supplementary Worksheet 5d for a list of transitions used in quantification).
SRM data were processed using MultiQuant 1.1 (ABSciex) with the MQL algorithm for peak integration. A 3-point smooth with a peak-splitting factor of 2 and the default MultiQuant values for noise percentage and baseline subtraction window were used. Multiple transitions for the peptide of interest were required to have the same retention time as the internal standard (Supplementary Worksheets 4c and 5d . All data were manually inspected to ensure correct peak detection and accurate integration. Integration results were exported to the program R for linear regression and statistical analysis. Linear regression was used to fit the ten serial dilution data points for each curve. Regression was performed using a 1/y weighting on all points having a correlation coefficient of >0.98. Precision was determined by measuring the coefficient of variation (CV, s.d. divided by the mean) and expressed as a percent. LOD and LOQ for each target were obtained by using the average of the blank measurements plus three times the s.d. of the noise (for LOD) and ten times the s.d. of the noise (for LOQ). To ensure the most reliable measurements, an additional constraint was applied to the LOQ where the average CV at the two concentration points nearest the calculated LOQ must be less than 25% 40, 41 . For assays where the condition was not met, the next highest concentration point where CV < 25% was considered the LOQ for that target.
Verification studies using a 57-plex SRM-MS assay. Individual plasma samples for the 57-plex Q-SRM verification studies were depleted using a Seppro IgY-M7 LC2 column system (Sigma-Aldrich) as described above, with the following additional considerations. To avoid bias in sample processing, individual samples were processed in 3 batches, based on the mouse cohorts: preclinical, clinically apparent and confounding. Pre-clinical and clinically apparent cohort samples were processed as cage-matched case and control pairs, while confounding condition samples were randomly assigned numbers one through ten, and individual samples were assigned to groups via these numbers. Pairs or groups were depleted as described above. Blanks were run between each sample. UV traces were used to confirm uniformity of depletion.
Following depletion, individual plasma samples were digested as follows; 9 M urea, 300 mM Tris, pH 8, and 20 mM DTT were added to a final concentration of 6 M, 150 mM, and 13.3 mM, respectively. Denaturation, reduction, alkylation, and digestion were carried out as described above. After digestion, the samples were desalted with 10 mg Oasis C18 columns (Waters Corporation) as described above, and bound peptides were eluted with 3 washes of 80% acetonitrile/0.1% formic acid. A mixture containing each of the 57 stable isotope-labeled peptides was prepared at different concentrations, based on the expected concentration of the endogenous peptide in each sample. Samples for LC-SRM-MS analysis were prepared by combining the depleted and digested sample with the mixture of 57 peptides.
Depleted and digested plasma samples were analyzed on an Eksigent nanoLC-Ultra 2Dplus (Eksigent Technologies) coupled to a 5500 QTRAP (ABSciex, Foster City, CA) mass spectrometer. Mobile phases consisted of 0.1% formic acid in water (A) and 90% acetonitrile with 0.1% formic acid (B). 15 µl of sample (corresponding to about 1.5 µl of depleted plasma) was loaded onto a 0.2 × 5 mm Chromolith CapRod RP-18e Trap column (EMD Chemicals) for 3 min at 10 µl/min with 5% mobile phase B. The peptides were then separated by a 0.05 × 150 mm Chromolith CapRod RP-18e column (EMD Chemicals) by the following gradient method: hold 5% B for 6 min, gradient from 10 to 30% B for 30 min, gradient from 30 to 40% B for 5 min, gradient from 40 to 90% B for 1 min, hold 90% B for 5 min, re-equilibrate at 5% B for 14 min. The flow rate was 600 nl/min. The trap column was back-flushed during the last 5 min of a run using 5% B at 10 µl/min. The LC system was coupled to the 5500 QTRAP mass spectrometer by an Advance CaptiveSpray source (Michrom Bioresources). The MS was used in positive ion mode with typical source parameters consisting of a 1,200 V ion spray voltage, curtain gas setting of 10, nebulizer gas setting of 0 and an interface heater temperature of 110 °C. For each run, the acquisition of 57 peptides was scheduled using a 420 s SRM detection window and a 1. Data 1, mouseQSRM_targets.sky) containing peptide sequences and SRM transitions is also available as a supplementary file. Each sample was run in triplicate. SRM data were processed using MultiQuant 1.1 (ABSciex) with the MQL algorithm for peak integration. A 3-point smooth with a peak-splitting factor of 2 and the default MultiQuant values for noise percentage and baseline subtraction window were used. Multiple transitions for the peptide of interest were required to have the same retention time as the internal standard. All data were manually inspected to ensure correct peak detection and accurate integration. Integration results were exported to the program R for linear regression and statistical analysis. More details are provided in Supplementary Results Section 6.
Verification studies using the 31-plex SISCAPA-SRM-MS assay. Sample digestion and SISCAPA enrichment were performed in triplicate (using 10 µl of plasma per replicate) for each individual mouse as follows. Ten microliters of plasma was diluted with 300 mM Tris, pH 8, containing 9 M urea and 30 mM dithiothreitol to yield 6 M and 20 mM final concentrations of urea and dithiothreitol, respectively. The plasma was incubated for 30 min at 37 °C, and 500 mM iodoacetamide was added to yield a final concentration of 40 mM. The samples were then incubated in the dark for 30 min at 25 °C, diluted 10 times with 100 mM Tris, pH 8, and incubated with trypsin (V5280, Promega) at 37 °C for 16 h using an enzyme-to-substrate ratio of 1:50. The pH of the digests was lowered by addition of formic acid to a final 1% concentration. For the clinically apparent and confounding condition mouse plasma samples, a mixture containing 200 fmol of each of the 31 stable isotope-labeled peptides was added. Oasis C18 resins (Waters) were conditioned with 3 × 0.4 ml of 80% acetonitrile in 0.1% formic acid and equilibrated with 4 × 0.4 ml of 0.1% formic acid. To lower nonspecific binding to the resins, the resins were additionally conditioned with 10 µL of a human plasma tryptic digest. Subsequently, the mouse plasma samples were loaded onto the resins and the resins were washed using 4 × 0.4 ml of 0.1% formic acid. The desalted peptides were eluted from the columns with 3 × 0.4 ml of 80% acetonitrile in 0.1% formic acid. Samples were dried by vacuum centrifugation and frozen at −80 °C until use. For the preclinical mice, Oasis C18 resins were conditioned with acetonitrile and formic acid as above and the mouse plasma digests were loaded onto the columns. The columns were washed with 4 × 0.4 ml of 0.1% formic acid and the peptides were eluted with 3 × 0.4 ml of 80% acetonitrile in 0.1% formic acid. The eluted peptides were dried, reconstituted with 0.1% formic acid containing 200 fmol of each of the 31 stable isotope-labeled peptides and loaded once again on their respective C18 resins. The washing and elution steps were repeated as above and the samples were dried and frozen at −80 °C.
Immuno-enrichment of the peptides by SISCAPA was carried out in 96-well polypropylene plates (Fischer Scientific) as described previously 43 , with 31 anti-peptide polyclonal antibodies multiplexed for each capture. For each individual replicate, 10 µL of digested plasma were reconstituted in 30 µL of PBS, and the pH of the samples was adjusted to neutral. For the preclinical and confounding mouse plasma samples, a mixture containing 1 µg of each of the 31 anti-peptide antibodies was added and PBS and CHAPS were added to reach a 100 µl final capture volume for each sample in each well (0.03% final CHAPS concentration). The samples were incubated overnight with gentle mixing at 4 °C. Subsequently, the plate was put into a KingFisher magnetic bead processing platform (Thermo Fisher). Forty-five microliters of protein Gimmobilized magnetic beads (MyOne, Invitrogen) were added to the samples and mixed for 2 h at 25 °C. The beads were then washed twice with PBS containing 0.03% CHAPS and once with 1/100 PBS + 0.03% CHAPS. The peptides were eluted using 13 µl of 5% acetic acid containing 0.03% CHAPS and the eluates were frozen at −80 °C until analysis by liquid chromatography-selected reaction monitoring-MS (LC-SRM-MS). For the peptide enrichment of the clinically apparent mouse plasma samples, 1 µg of each of the 31 anti-peptide antibodies was incubated with 10 µl of plasma peptides, 45 µl of protein Gimmobilized magnetic beads, and PBS + 0.03% CHAPS at the same time in a total capture volume of 120 µl. The plate was taped to a tumbler and incubated overnight at 4 °C while tumbling to keep the beads in suspension. The washing and elution steps were performed as above for the preclinical and confounding samples, with a 25 µl elution volume.
The LC system consisted of an Eksigent 2DLC system (Eksigent Technologies) configured with a nano autosampler and two external 10-port microvalves. Mobile phases consisted of 0.1% formic acid in water (A) and 90% acetonitrile with 0.1% formic acid (B). 10 µl of sample was loaded onto a 0.3 × 5 mm PepMap Acclaim C18 trap column (Dionex) for 1.5 min at 10 µl/min with 3% mobile phase B. The peptides were then separated using a 0.075 × 100 mm column (PicoFrit, New Objective) packed in-house with 3 µm ReproSil-Pur C18-AQ particles (Dr. Maisch). The PicoFrit column had a 10 µm inner diameter emitter tip. A 12 min gradient was developed from 3 to 50% B using 300 nl/min, after which solvent B was increased to 90% over 2 min and held at 90% for 3 min. The column was subsequently re-equilibrated at 3% B for 17 min (for 8 of the 17 min, the flow rate was increased to 400 nl/min to speed up the equilibration). The trap column was back-flushed during the last 2 min of a run using 3% B at 10 µl/min. The LC system was connected via a nanoelectrospray interface to a 4000 QTRAP (ABSciex) that was used in positive ion mode. Typical source parameters consisted of a 2300 V ion spray voltage, curtain gas and nebulizer gas settings of 15 and 12, respectively, and an interface heater temperature of 150 °C. For each run, the acquisition of 31 peptides was scheduled using a 90 s SRM detection window and a 0.5 s cycle time. Six transitions were monitored for each peptide (3 light and 3 heavy transitions), see Supplementary Worksheet 5c for a complete list of transitions. A Skyline 42 document containing peptide sequences and SRM transitions is also available as Supplementary Data 2 (mouseImmunoSRM_targets.sky).
SRM data were processed using MultiQuant 1.1 (ABSciex) with the MQL algorithm for peak integration. A 3-point smooth with a peak-splitting factor of 2 and the default MultiQuant values for noise percentage and baseline subtraction window were used. Multiple transitions for the peptide of interest were required to have the same retention time as the internal standard. All data were manually inspected to ensure correct peak detection and accurate integration. Integration results were exported to R for linear regression and statistical analysis. More details are provided in Supplementary Results Section 6. 
